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Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, with coronary 1 
heart disease (CHD) accounting for more than 50% of cases. While recent advances in treatment 2 
have led to CVD dipping below cancer as the leading cause of death in some high income countries, 3 
it is important to note that 80% of CVD deaths now occur in low and middle-income countries.1,2 4 
It has long been understood that factors contributing to this large global burden of disease include 5 
hypertension, smoking, physical inactivity, obesity and hypercholesterolaemia.2,3 However, these 6 
variables alone do not fully explain the association. More recently, a wealth of evidence has linked 7 
low socioeconomic status (SES) to adverse CV outcomes.4 This evidence has led to SES being 8 
incorporated into some risk scores for CV disease, including the ASSIGN score ("ASSessing 9 
cardiovascular risk using SIGN")5 and QRISK3 score,6 although interestingly, SES has not yet been 10 
fully incorporated into SCORE: the European risk score calculator.7 This strong independent link 11 
between socioeconomic status and cardiovascular outcomes has fuelled research to try and 12 
determine the underlying mechanisms. Potential factors have included SES-driven differences in 13 
smoking, alcohol, obesity, healthcare accessibility,4 diet and inflammation,4,8 and recent data from 14 
UK Biobank suggest that socioeconomic deprivation potentiates the adverse association between 15 
unhealthy lifestyle factors and (CVD and all-cause) mortality.9 However, other unmeasured factors 16 
are also likely to be relevant. 17 
 18 
In recent years, sleep has evolved as a potential lifestyle factor which may be relevant to both 19 
metabolic and cardiovascular risk. In a meta-analysis of self-reported sleep duration and 20 
cardiovascular outcomes in prospective studies, Cappuccio et al, found a ‘U-shaped’ association 21 
between sleep duration and risk of developing CHD with both shorter and longer durations of sleep 22 
being associated with a greater risk of developing or dying from CHD and stroke disease.10 The 23 
accumulating evidence was thought sufficiently robust for a recent USA-based CVD prevention 24 
guideline recommending targeting short sleep duration and poor sleep quality as another method to 25 
help lessen risk.11 26 
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In this issue of Cardiovascular Research, Petrovic and colleagues report the results of a large 1 
observational study on eight European Cohorts with a total of more than 111,000 participants. They 2 
investigate the role of sleep duration in explaining socioeconomic status links to cardiovascular 3 
disease. Their data suggest that both father’s and adult occupational position are associated with 4 
abnormal sleep duration patterns, with a stronger association for short sleep than long sleep. In 5 
addition, they found an inverse association between both life-course SES indicators and CHD, and 6 
that the association between adult occupational position and CHD was partly explained by short 7 
sleep duration, at least in men. This study has multiple strengths including its large size and being 8 
the first to investigate sleep duration and CV disorders across life socioeconomic status. However, 9 
there are some limitations which include recall bias of self-reported sleep duration and lack of 10 
adjustment for some potential confounders including hypertension, hyperlipidaemia and 11 
environmental factors. Even so, this paper adds key insights into our understanding of the 12 
associations between SES, sleep and CVD. 13 
 14 
Nevertheless, how can we determine whether shorter or longer sleep durations are causal risk 15 
factors for adverse CVD outcomes? Here we have to turn to genetic studies. Dashti et al identified 78 16 
(76 novel) gene loci for sleep duration that implicate multiple biological pathways. They then 17 
compared observational and genetic data linking sleep to adverse outcomes.12 Whilst observational 18 
data showed short sleep was associated with a 20% higher multivariate adjusted risk of incident 19 
myocardial infarction and long sleep with a 34% higher risk, Mendelian randomisation analyses using 20 
the discovered sleep genes was consistent only with a casual effect of shorter sleep duration on 21 
myocardial infarction in both CARDIoGRAMplusC4D and UK Biobank13 (Figure 1). Thus while the 22 
mechanisms underpinning the association between long sleep duration and CVD risk are still unclear 23 
– this may reflect reverse causality (i.e. those with pre-existing illness sleeping longer) or poor sleep 24 
quality, which in itself may increase CHD risk,14 thereby necessitating longer sleep duration to feel 25 
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rested – there is accumulating evidence that short sleep is likely to play a causal role in mediating 1 
CVD risk. 2 
 3 
If all of the above is true, can we help short sleepers sleep longer? Recently in a randomised clinical 4 
trial of 1711 people, Espie and colleagues reported that the use of digital cognitive behavioural 5 
therapy is effective in improving functional health, psychological wellbeing and sleep-related quality 6 
of life in people reporting insomnia symptoms.15 This trial suggested that sleep interventions can 7 
improve insomnia symptoms as well as functional health, psychological well-being and sleep-related 8 
quality of life. Extending such research, it should be possible to conduct a randomised trial of sleep 9 
interventions for the prevention of CV disease or diabetes (Figure 1). Such trials would take time, 10 
effort, and careful design, but they are needed if sleep interventions are to have wider impact in 11 
preventative medicine. Only by showing sleep interventions improve either proven casual risk 12 
factors, or better hard outcomes, will sleep interventions hit prime time in the CV and metabolic 13 
arenas.  14 
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Figure Legend 1 
This figure depicts the observational associations between sleep duration and cardiovascular 2 
outcomes. Generally, both short and long sleep are associated with greater CV risks compared to 3 
those who sleep between 6 to 9 hours per night. That noted, recent genetic work suggest shorter 4 
sleep may be causally linked to such CV outcomes whereas this appears not to be the case for longer 5 
sleep durations. As many conditions can lead people to sleep for longer, this association may 6 
represent reverse causality or residual confounding. In particular, long sleep may be a consequence 7 
of poor sleep quality, which in itself may be associated with CHD risk. The totality of work sets the 8 
scene for sleep intervention trials in the cardiovascular arena. 9 
 10 
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